主题评价:
  • 0 次(票) - 平均星级: 0
  • 1
  • 2
  • 3
  • 4
  • 5
of febrile neutropenia were higher in patients receiving trastuzumab products in
#1
morning or before cocktail hour For many cancer patients in the US, battling cancer has not only been a health issue, but a considerable financial burden brought on
http://selfcatering.hu/component/kunena/...ing#532013
by cancer treatment. Biosimilars are intended to be lower cost, high-quality treatment options that have the potential to alleviate such burden. We sincerely hope our trastuzumab biosimilar will do exactly that,” said Sang-Jin Pak, Senior Vice President and Head of Commercial Division, Samsung Bioepis. “At
http://poligonoindustrial.sanisidro.es/f...ntaciones/
Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening the availability of approved treatments for cancer patients across the US. In randomized, controlled clinical trials, the per-patient incidences of NCI-CTC Grade 3-4 neutropenia and
http://mmonly.cn/web/viewtopic.php?p=10484#10484
回复


论坛跳转:


正在浏览该主题的用户: 1 个游客